Avacta names Prof. Gerard Evans to its Scientific Advisory Board

Avacta Group, the developer of Affimer biotherapeutics and research reagents has appointed Professor Gerard Evan, FRS, to its Scientific Advisory Board. Avacta expressed joy in its press release on Monday, as it welcomed professor Evan’s expertise in immuno-oncology and cancer stem cell research to support the its development of oncology biotherapeutics based on its proprietary Affimer technology.

Professor Evan’s research focuses on the molecular basis of cancer. He was formerly Gerson and Barbara Bass Baker Distinguished Professor of Cancer Biology at the University of California San Francisco and Co-leader of the Cell Cycling and Signaling Program at the UCSF Comprehensive Cancer Center. In 2009 he was elected to the Sir William Dunn Chair of Biochemistry and Head of Biochemistry in the University of Cambridge.

 Professor Evan has a BA in Biochemistry from the University of Oxford and a PhD in Molecular Immunology from the University of Cambridge. He was awarded the Pfizer prize in Biology in 1995, and in 1996 was elected as the Royal Society’s Napier Professor of Cancer Research. He is a Fellow of the Royal Society, the UK Academy of Medical Sciences and the European Molecular Biology Organization. Professor Evan has also held the Neal Levitan Research Chair of the Brain Tumor Society and a Senior Scholarship from the Ellison Medical Research Foundation for Aging.

 Alastair Smith, Avacta Group Chief Executive, commented: 

“We are delighted that Professor Evan has joined Avacta’s therapeutics Scientific Advisory Board. His deep knowledge of the molecular mechanisms of cancer will be a great asset to the Company and in particular his pioneering work in the area of cancer stem cell biology could help create novel and highly valuable Affimer therapies in this emerging area.

 Gerard is joining us at an exciting time. We recently announced the important milestone of achieving positive results from the first animal safety and efficacy studies with our lead immuno-oncology candidate, a PD-L1 immune checkpoint inhibitor. This success, and the continued good progress across all other programmes in the past year, has served to further strengthen our belief that the Affimer technology has huge potential as a therapeutic platform and in other non-therapeutic applications. We continue to focus on developing both our internal and partnered therapeutic programmes towards clinical validation and on commercialising Affimer reagents in multiple markets.”

Leave a Reply

Please log in using one of these methods to post your comment:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s